|Endothelial Cell Counts are Required for ICL Implantation|
An endothelial cell count to verify that a patient's cornea has an adequate endothelial cell density is an FDA labeling requirement for patient screening and selection prior to implantation of phakic intraocular lenses (Intraocular Contact Lenses, or "ICLs").
Without an adequate endothelial cell count, the current ICLs are contraindicated for implantation and clearly highlights the importance of this screening procedure. Endothelial cell density must be accurately checked preoperatively to ensure that a patient is a suitable candidate, and then should be monitored periodically postoperatively to verify the endothelium's continued health. Although an endothelial cell count can be crudely estimated using card developed in the 1980's, this technique has significant limitations that are now well answered with Konan's specular microscopy technologies:
Theodore Perl, MD in "Avoiding Complications with Phakic IOLs", Cataract and Refractive Surgery Today, October 2009 counsels that it "is important to select patients whose endothelial cell density and morphology are normal."
Vance Thompson, MD in "Phakic IOL's Find a Solid Niche" Ophthalmology Management, September 2009 describes the importance of safety data point by requiring "every phakic lens candidate to have a minimum of 3.2 mm anterior chamber depth and a baseline endothelial cell count of more than 2,000."
Visian ICL™, Staar Surgical™, Verisyse™, Abbot Medical Optics™, AcrySof® Cachet™, and ALCON® are trademarks of their respective owners.